青光眼治疗药的全球市场(2024年):市场分析(2023年～2029年)

本报告调查了全球青光眼治疗市场，涵盖品牌前列腺素、仿製药前列腺素、β-阻断剂、碳酸酐?抑製剂、α-激动剂、固定组合药物、NO 捐赠化合物，显示了到2029 年Rho 激?抑制剂的预测。它还广泛讨论了管道产品，涵盖目前正在开发的 30 多种候选药物。此外，我们还介绍了 26 家青光眼製药公司，提供他们的产品、策略市场地位、背景和前景。

目录

• 青光眼种类与危险因素
• 疾病诊断与治疗
• 眼科医生和含验光师的青光眼医疗提供者的全球见解
• 全球疾病盛行率预测(5年)
• 市场上青光眼治疗药和那个作用机制
• 学名药和品牌医药品的比较和对市场的影响
• 青光眼医药品的开发平台
• 製造·销售青光眼治疗药的企业的简介

What's New:

The "2024 Glaucoma Pharmaceuticals Market Report" features new regional sales forecasts that take into account appreciation of the dollar against other major currencies and an updated analysis of the prevalence and diagnosis of glaucoma that reflects COVID-19 mortality. The report now includes market share analysis of generics and branded drugs by drug class in the United States and Japan and prescription stratification by first-line and adjunctive use in the United States and Western European countries.

This new report also provides an updated analysis of the glaucoma pharma product pipeline, a summary of ongoing clinical trials, a review of Glaukos' recently approved iDose TR sustained drug delivery device, and survey data on US ophthalmologists' plans for sustained drug delivery.

The "2024 Glaucoma Pharmaceuticals Market Report" analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2029 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 26 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook.

This report provides analysis of current markets for glaucoma medications and forecasts market performance over the next five years. The global market is analyzed based on Market Scope's eight regional/economic categories (the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World), and also uses these categories in global forecasts for disease prevalence. In addition, the report explores data and information on the disease process, glaucoma populations, glaucoma care, and a range of additional topics intended to provide depth and context to the reader's understanding of this ophthalmic segment. Coverage includes:

• Types of glaucoma and risk factors.
• Diagnosis and treatment of the disease.
• A global view of glaucoma care providers, including ophthalmologists and optometrists.
• Current estimates and five-year forecasts for disease prevalence worldwide.
• Glaucoma medications in the marketplace and their mechanisms of action.
• Discussion of generic versus branded drugs and their market impact.
• The development pipeline for glaucoma pharmaceuticals.
• Profiles of companies making and marketing glaucoma medications.

Author Profile:

Peter Downs

Peter Downs Peter Downs has more than 30 years of experience as a business and medical journalist and investigative reporter. He has written for a variety of medical industry publications, including the Medical Business Journal, CBS HealthWatch, and Oncology News International.

Prior to joining Market Scope in 2015 and turning his attention to ophthalmology, Peter analyzed markets for organ and tissue transplantation. Since joining Market Scope, he has traveled to several markets outside the US, including China, Europe, and India, to study ophthalmology at the local level.

In addition to his research and writing efforts on the ophthalmic market, he is also a contributor to Ophthalmic Market Perspectives, the firm's monthly industry newsletter.